

# Simiso Sokhela

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3691834/publications.pdf>

Version: 2024-02-01

17  
papers

804  
citations

1039880

9  
h-index

940416

16  
g-index

18  
all docs

18  
docs citations

18  
times ranked

971  
citing authors

#	ARTICLE	IF	CITATIONS
1	Concentrationâ€“response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 883-893.	1.1	9
2	Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2022, 226, 1616-1625.	1.9	3
3	<i>CYP2B6</i> Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. <i>Clinical Infectious Diseases</i> , 2021, 73, e3902-e3909.	2.9	54
4	High individual pain variability in people living with HIV: A graphical analysis. <i>European Journal of Pain</i> , 2021, 25, 160-170.	1.4	0
5	Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e1008-e1010.	2.9	15
6	Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir- and Tenofovir-containing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 1002-1009.	0.9	6
7	Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. <i>Aids</i> , 2021, 35, 1657-1665.	1.0	40
8	The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. <i>Aids</i> , 2021, 35, S117-S125.	1.0	12
9	Weight gain stopping/switch rules for antiretroviral clinical trials. <i>Aids</i> , 2021, 35, S183-S188.	1.0	15
10	Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. <i>Aids</i> , 2021, 35, S173-S182.	1.0	5
11	Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. <i>Aids</i> , 2020, 34, 321-324.	1.0	4
12	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2020, 7, e666-e676.	2.1	145
13	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. <i>Journal of Virus Eradication</i> , 2020, 6, 70-73.	0.3	20
14	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. <i>Journal of Virus Eradication</i> , 2020, 6, 70-73.	0.3	4
15	Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. <i>New England Journal of Medicine</i> , 2019, 381, 803-815.	13.9	447
16	Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2019, 6, e428-e437.	2.1	14
17	Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 224-233.	0.9	11